(NASDAQ: HROW) Harrow's forecast annual revenue growth rate of 38.51% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 8.99%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.34%.
Harrow's revenue in 2026 is $268,675,000.On average, 10 Wall Street analysts forecast HROW's revenue for 2026 to be $13,244,591,019, with the lowest HROW revenue forecast at $12,518,844,686, and the highest HROW revenue forecast at $13,773,152,037. On average, 10 Wall Street analysts forecast HROW's revenue for 2027 to be $19,602,606,020, with the lowest HROW revenue forecast at $16,712,294,223, and the highest HROW revenue forecast at $22,563,740,520.
In 2028, HROW is forecast to generate $26,873,861,143 in revenue, with the lowest revenue forecast at $23,644,345,872 and the highest revenue forecast at $30,752,708,777.